Insights into Renal Cell Carcinoma (RCC) 2020 (Northeast)

Current treatment practice attitudes toward therapy of unresectable advanced renal cell carcinoma (RCC), recently introduced and upcoming agents

Northeast – November 16, 2020

Faculty Chair

Bradley A. McGregor, MD

Dana-Farber Cancer Institute, Boston, M

Example Report

Start discovering the insights

View Report


  • A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of advanced RCC was held on November 16, 2020, in a virtual setting
  • Disease state and data presentations were developed in conjunction with Bradley A. McGregor, MD, a medical expert from Dana-Farber Cancer Institute
  • The group of advisors comprised 10 community oncologists from the northeast United States
  • Insights on the following therapies were obtained: sunitinib, pazopanib, cabozantinib, axitinib, lenvatinib, ipilimumab, pembrolizumab, nivolumab, avelumab, everolimus, and combinations of these drugs


  • Data collection was accomplished through use of audience response system (ARS) questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from Maine, Massachusetts, New Hampshire, and Vermont

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.